Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
J Cardiovasc Pharmacol Ther. 2013 Mar;18(2):162-76. doi: 10.1177/1074248412465015. Epub 2012 Nov 8.
To investigate the mechanism of rosuvastatin in preserving cardiac function after acute myocardial infarction (AMI) in a rat model.
Sprague-Dawley rats were randomized to receive either rosuvastatin (5 mg/kg every day) or placebo (0.5% CMC-Na), respectively, by daily gavage from 7 days before AMI. Acute myocardial infarction (AMI) model was induced by left anterior descending coronary artery ligation through a lateral thoracotomy in rats. The expressions of stromal-cell-derived factor 1 (SDF-1), chemokine motif CXC receptor 4 (CXCR-4), vascular endothelial growth factor (VEGF), and intercellular adhesion molecule 1 (ICAM-1) in peri-infarction region and nonischemic region at different time points were determined by the Western blot analysis. Immunohistochemistry analysis was performed on the 28th day after AMI to investigate the accumulation of CD90+, CD133+, and c-kit+ progenitor cells in the peri-infarction region. Masson staining and echocardiograph were performed to evaluate the left ventricular remodeling and postinfarction cardiac function 4 weeks after AMI.
Western blot analysis showed that rosuvastatin could change the cytokine expressions in the peri-infarction region by upregulating the SDF-1 expression and downregulating the expressions of CXCR-4, ICAM-1, and VEGF in 4 to 14 days after AMI. Immunohistochemistry analysis showed that rosuvastatin treatment was associated with increased accumulation of CD90+, CD133+, and c-kit+ progenitor cells in the peri-infarction region. Masson staining and echocardiograph confirmed that rosuvastatin could attenuate left ventricular remodeling and improve postinfarction systolic function.
The data suggest that rosuvastatin can protect the heart from ischemic injury and preserve the cardiac function in rats in vivo. The changing expressions of SDF-1, CXCR-4, ICAM-1, and VEGF, and the accumulation of progenitor cells were involved in this process.
研究瑞舒伐他汀在大鼠急性心肌梗死(AMI)模型中保护心功能的机制。
通过每日灌胃,分别给予 Sprague-Dawley 大鼠瑞舒伐他汀(5mg/kg 每天)或安慰剂(0.5%CMC-Na),从 AMI 前 7 天开始。通过开胸术结扎左前降支在大鼠中诱导 AMI 模型。通过 Western blot 分析,在不同时间点测定梗死周边区和非缺血区基质细胞衍生因子 1(SDF-1)、趋化因子基序 CXC 受体 4(CXCR-4)、血管内皮生长因子(VEGF)和细胞间黏附分子 1(ICAM-1)的表达。在 AMI 后 28 天进行免疫组织化学分析,以研究梗死周边区 CD90+、CD133+和 c-kit+祖细胞的积累情况。Masson 染色和超声心动图用于评估 AMI 后 4 周左心室重构和梗死后心功能。
Western blot 分析显示,瑞舒伐他汀可通过上调 SDF-1 的表达和下调 AMI 后 4 至 14 天 CXCR-4、ICAM-1 和 VEGF 的表达来改变梗死周边区的细胞因子表达。免疫组织化学分析显示,瑞舒伐他汀治疗与梗死周边区 CD90+、CD133+和 c-kit+祖细胞的积累增加有关。Masson 染色和超声心动图证实,瑞舒伐他汀可减轻左心室重构并改善梗死后收缩功能。
数据表明,瑞舒伐他汀可保护大鼠体内的心脏免受缺血性损伤并维持心功能。这一过程涉及 SDF-1、CXCR-4、ICAM-1 和 VEGF 的表达变化以及祖细胞的积累。